Stock Events

Stock Events

Acurx Pharmaceuticals 

$1.4150
68
+$0.05+4.04% 18:42 Today

Statistics

Day High
1.5299
Day Low
1.36
52W High
10
52W Low
1.35
Volume
755,261
Avg. Volume
-
Mkt Cap
6.08M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-2.6
-1.78
-0.96
-0.15
Expected EPS
-0.376667
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
0Revenue
-28.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACXP. It's not an investment recommendation.
Tesla
5
TSLA
NVIDIA
5
NVDA
Palantir Technologies
5
PLTR
Super Micro Computer
5
SMCI

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Merck
MRK
Mkt Cap319.99B
Merck & Co., Inc. is a global healthcare company that develops antibiotics and treatments for infectious diseases, directly competing with Acurx's focus on developing novel antibiotics.
Pfizer
PFE
Mkt Cap138.61B
Pfizer Inc. is involved in the discovery, development, and manufacture of healthcare products including antibiotics, making it a competitor in the infectious disease space.
GSK
GSK
Mkt Cap107.47B
GlaxoSmithKline plc engages in the creation and discovery of pharmaceutical products, including antibiotics, competing in the same market as Acurx Pharmaceuticals.
Abbvie
ABBV
Mkt Cap461.26B
AbbVie Inc. researches and develops a broad range of pharmaceuticals including treatments for infectious diseases, positioning it as a competitor.
Johnson & Johnson
JNJ
Mkt Cap633.19B
Johnson & Johnson engages in the research and development of pharmaceuticals, including those for infectious diseases, making it a competitor in the healthcare sector.
Novartis
NVS
Mkt Cap305.1B
Novartis AG focuses on the discovery, development, and marketing of healthcare products, including antibiotics, which places it in competition with Acurx.
AMGEN
AMGN
Mkt Cap201.93B
Amgen Inc. is a biotechnology company that develops innovative human therapeutics, including treatments for infections, competing in the biopharmaceutical space.
Bristol-Myers Squibb
BMY
Mkt Cap118.71B
Bristol-Myers Squibb Company discovers, develops, and delivers innovative medicines, including those for infectious diseases, competing with Acurx's product pipeline.
Sanofi
SNY
Mkt Cap103.32B
Sanofi engages in the research, development, and marketing of pharmaceutical products, including antibiotics, making it a direct competitor.
Astrazeneca
AZN
Mkt Cap302.65B
AstraZeneca PLC is a global, science-led biopharmaceutical company that develops a range of pharmaceuticals, including those for bacterial infections, directly competing with Acurx Pharmaceuticals.

About

Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Show more...
CEO
Mr. Robert J. DeLuccia
Employees
4
Country
United States
ISIN
US00510M2035

Listings

F
DE
3ZO0.F
XNAS
US
ACXP
STU
DE
3ZO0.STU
MU
DE
3ZO0.MU

0 Comments

Share your thoughts

FAQ

What is Acurx Pharmaceuticals stock price today?▼
The current price of ACXP is $1.42 USD — it has increased by +4.04% in the past 24 hours. Watch Acurx Pharmaceuticals stock price performance more closely on the chart.
What is Acurx Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Acurx Pharmaceuticals stocks are traded under the ticker ACXP.
Is Acurx Pharmaceuticals stock price growing?▼
ACXP stock has fallen by -11.25% compared to the previous week, the month change is a -11.8% fall, over the last year Acurx Pharmaceuticals has showed a -85.8% decrease.
What is Acurx Pharmaceuticals market cap?▼
Today Acurx Pharmaceuticals has the market capitalization of 6.08M
When is the next Acurx Pharmaceuticals earnings date?▼
Acurx Pharmaceuticals is going to release the next earnings report on August 17, 2026.
What were Acurx Pharmaceuticals earnings last quarter?▼
ACXP earnings for the last quarter are -0.62 USD per share, whereas the estimation was -1.2 USD resulting in a +48.33% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Acurx Pharmaceuticals revenue for the last year?▼
Acurx Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Acurx Pharmaceuticals net income for the last year?▼
ACXP net income for the last year is -28.21M USD.
How many employees does Acurx Pharmaceuticals have?▼
As of July 09, 2026, the company has 4 employees.
In which sector is Acurx Pharmaceuticals located?▼
Acurx Pharmaceuticals operates in the Health & Wellness sector.
When did Acurx Pharmaceuticals complete a stock split?▼
The last stock split for Acurx Pharmaceuticals was on August 05, 2025 with a ratio of 1:20.
Where is Acurx Pharmaceuticals headquartered?▼
Acurx Pharmaceuticals is headquartered in Staten Island, United States.